{
    "clinical_study": {
        "@rank": "148177", 
        "acronym": "BMSCT", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Bone Marrow Stem Cell transplantation may\n      improve Assisted Reproduction Techniques (ART) outcomes in refractive Asherman's Syndrome or\n      Atrophic Endometrium."
        }, 
        "brief_title": "Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Asherman's Syndrome", 
            "Endometrial Atrophy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gynatresia", 
                "Atrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "This novel technique refers to the use of CD133+ autologous bone marrow stem-cells to\n      regenerate the endometrium in patients with Asherman's Syndrome, Endometrial Atrophy or any\n      condition that produce a destruction of the endometrium or its de novo creation in a\n      bioengineered uterus.\n\n      It requires a previous mobilization in the peripheral blood of CD133+ autologous bone marrow\n      stem cells, subsequent apheresis and transplant of the same cells in the spiral arterioles\n      of the uterus with the aim to regenerate de novo the endometrium. This technique represents\n      a new therapeutical approach for the treatment of endometrial regeneration problems such\n      Asherman Syndrome and the endometrial atrophy since currently no specific treatment for\n      these endometrial pathologies exist.\n\n      A prospective experimental non controlled study has been designed in order to assess the\n      effectiveness of these technique as a new tool for treat Asherman's Syndrome and Endometrial\n      Atrophy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed of Asherman Syndrome and absence of pregnancy after treatment\n\n          -  Endometrial atrophy (<6mm) with Implantation Failure\n\n          -  Age 20-45 years-old\n\n          -  Normal liver, heart  and kidney function\n\n          -  Presence of menstrual bleeding with Natural Cycle or HRT\n\n          -  Absence of psychiatric pathology and ability to accomplish the treatment\n\n          -  \u03b2-hCG negative\n\n          -  Absence of SDT\n\n        Exclusion Criteria:\n\n          -  Absence of peripheral vein access\n\n          -  Lack of accomplish inclusion criteria"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144987", 
            "org_study_id": "1101-C-092-JS"
        }, 
        "intervention": {
            "description": "Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.\nBMSC recollection  with apheresis procedure and positive selection of the CD133+ cells.\nThe selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.\nCD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization\nSubsequently Hormonal Replacement Therapy (HRT) will be given to the patients\nHysteroscopy will be performed 2-3 months after stem cell transplantation\nEmbryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation", 
            "intervention_name": "Bone Marrow CD133+ Stem Cell Transplantation", 
            "intervention_type": "Biological", 
            "other_name": "Neupogen"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mpeiro@incliva.es", 
                    "last_name": "Marta Peir\u00f3", 
                    "phone": "+963862894"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46010"
                    }, 
                    "name": "Hospital Clinico y Universitario de Valencia"
                }, 
                "investigator": [
                    {
                        "last_name": "Cristina Arbona, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Julio Palmero da Cruz, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Francisco Raga, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Joaquin Gil Romero, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Rosa Goterris Vicedo, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sergio.cabanillas@ivi.es", 
                    "last_name": "Sergio Cabanillas, MD", 
                    "phone": "+34 900 84 73 00"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46015"
                    }, 
                    "name": "Instituto Valenciano Infertilidad"
                }, 
                "investigator": {
                    "last_name": "Sergio Cabanillas, Md", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "New Therapeutic Approaches to Treat Asherman's Syndrome and Endometrial Atrophy Based in BM Stem Cells Autologous Transplantation", 
        "overall_contact": {
            "email": "xavier.santamaria@ivi.es", 
            "last_name": "Xavier Santamaria, MD, PhD", 
            "phone": "+34 932 06 30 00"
        }, 
        "overall_contact_backup": {
            "email": "carlos.simon@ivi.es", 
            "last_name": "Carlos Simon, MD, PhD", 
            "phone": "+34 900 84 73 00"
        }, 
        "overall_official": [
            {
                "affiliation": "Instituto Valenciano Infertilidad", 
                "last_name": "Xavier Santamaria, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Instituto Valenciano Infertilidad", 
                "last_name": "Carlos Simon, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
                "Spain: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Live birth rate is the percentage of all cycles that lead to live birth, and is the pregnancy rate adjusted for miscarriages and stillbirths.", 
                "measure": "Live-birth rate", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "description": "Ongoing pregnancy  rate is the percentage of all cycles that lead to presence of heartbeat in Ultrasound scan at the end of the first trimester", 
                "measure": "Ongoing pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Implantation rate is the percentage of embryos which successfully undergo implantation compared to the number of embryos transferred in a given period.", 
                "measure": "Implantation Rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "reference": [
            {
                "PMID": "14766732", 
                "citation": "Chan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod. 2004 Jun;70(6):1738-50. Epub 2004 Feb 6. PubMed"
            }, 
            {
                "PMID": "22276168", 
                "citation": "Cervell\u00f3 I, Gil-Sanchis C, Mas A, Faus A, Sanz J, Moscard\u00f3 F, Higueras G, Sanz MA, Pellicer A, Sim\u00f3n C. Bone marrow-derived cells from male donors do not contribute to the endometrial side population of the recipient. PLoS One. 2012;7(1):e30260. doi: 10.1371/journal.pone.0030260. Epub 2012 Jan 19. PubMed"
            }, 
            {
                "PMID": "19800602", 
                "citation": "Ikoma T, Kyo S, Maida Y, Ozaki S, Takakura M, Nakao S, Inoue M. Bone marrow-derived cells from male donors can compose endometrial glands in female transplant recipients. Am J Obstet Gynecol. 2009 Dec;201(6):608.e1-8. doi: 10.1016/j.ajog.2009.07.026. Epub 2009 Oct 3. PubMed"
            }, 
            {
                "PMID": "15238594", 
                "citation": "Taylor HS. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA. 2004 Jul 7;292(1):81-5."
            }, 
            {
                "PMID": "21712999", 
                "citation": "Cervell\u00f3 I, Mas A, Gil-Sanchis C, Peris L, Faus A, Saunders PT, Critchley HO, Sim\u00f3n C. Reconstruction of endometrium from human endometrial side population cell lines. PLoS One. 2011;6(6):e21221. doi: 10.1371/journal.pone.0021221. Epub 2011 Jun 21. PubMed"
            }, 
            {
                "PMID": "21772740", 
                "citation": "Nagori CB, Panchal SY, Patel H. Endometrial regeneration using autologous adult stem cells followed by conception by in vitro fertilization in a patient of severe Asherman's syndrome. J Hum Reprod Sci. 2011 Jan;4(1):43-8. doi: 10.4103/0974-1208.82360. PubMed"
            }, 
            {
                "PMID": "21549641", 
                "citation": "March CM. Management of Asherman's syndrome. Reprod Biomed Online. 2011 Jul;23(1):63-76. doi: 10.1016/j.rbmo.2010.11.018. Epub 2010 Dec 4. Review. PubMed"
            }, 
            {
                "PMID": "15705371", 
                "citation": "Zhang X, Chen CH, Confino E, Barnes R, Milad M, Kazer RR. Increased endometrial thickness is associated with improved treatment outcome for selected patients undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2005 Feb;83(2):336-40. PubMed"
            }, 
            {
                "PMID": "21076533", 
                "citation": "Sanz-Ruiz R, Guti\u00e9rrez Iba\u00f1es E, Arranz AV, Fern\u00e1ndez Santos ME, Fern\u00e1ndez PL, Fern\u00e1ndez-Avil\u00e9s F. Phases I-III Clinical Trials Using Adult Stem Cells. Stem Cells Int. 2010 Nov 4;2010:579142. doi: 10.4061/2010/579142. PubMed"
            }, 
            {
                "PMID": "19544220", 
                "citation": "M\u00e4kel\u00e4 J, Anttila V, Ylitalo K, Takalo R, Lehtonen S, M\u00e4kikallio T, Niemel\u00e4 E, Dahlbacka S, Tikkanen J, Kiviluoma K, Juvonen T, Lehenkari P. Acute homing of bone marrow-derived mononuclear cells in intramyocardial vs. intracoronary transplantation. Scand Cardiovasc J. 2009 Dec;43(6):366-73. doi: 10.1080/14017430903045350. PubMed"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144987"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Endometrial thickness measured with Ultrasound in a previous treatment with Hormonal Replacement Therapy", 
                "measure": "Endometrial thickness prior to the treatment", 
                "safety_issue": "No", 
                "time_frame": "0"
            }, 
            {
                "description": "Endometrial thickness measured with Ultrasound with Hormonal Replacement Therapy 3-6 months after Bone Marrow Stem Cell Transplantation", 
                "measure": "Endometrial Thickness after treatment", 
                "safety_issue": "No", 
                "time_frame": "3-6 months"
            }
        ], 
        "source": "Valencian Infertility Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Clinic Hospital Valencia", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Valencian Infertility Institute", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}